Cytoreduction and Regional Chemotherapy DMPM typically remains localized to the abdominal cavity, with spread to the pleura (via direct extension or transdiaphragmatic lymphatics) occurring rarely and only at advanced stages of disease. 11 , 15 , 17 Based on
Keli Turner, Sheelu Varghese, and H. Richard Alexander
Kamya Sankar and Brady L. Stein
). 9 Although hematologists hope to modify disease biology and prevent transformation to MF/AML, 9 this is not expected with current therapies. Cytoreduction is typically prescribed for patients with ET or PV who have a high risk for vascular
Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray
cytoreductive surgery for ovarian carcinoma . Gynecol Oncol 1995 ; 58 : 244 – 247 . 24 Gillette-Cloven N Burger RA Monk BJ . Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer . J Am Coll Surg 2001 ; 193 : 626
Joan How and Gabriela Hobbs
considered as well when evaluating a patient’s overall risk for thrombosis. 9 In addition to aspirin and the maintenance of a hematocrit (Hct) <45% in PV, 10 cytoreduction with hydroxyurea has resulted in improved thrombosis-free survival in high
Ying Zhou, Chenchen Zhu, Zhen Shen, Yanhu Xie, Wei Zhang, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Shuai Yin, Rongzhu Chen, Wei Wei, Sinan Sun, Guihong Wang, Zheng Zhou, Hanhui Yao, Dabao Wu, and Björn Nashan
Objective: To evaluate the postoperative complications and their impacts on the patients who have performed with primary cytoreduction (including extra upper abdominal surgery, EUAS) of advanced epithelial ovarian cancer at stage IIIc and IV
Michael P. Porter and Paul H. Lange
Renal tumors are a common cause of cancer, and renal cell carcinoma accounts for the vast majority of the renal tumors in the United States. The past two decades have produced numerous advances in the treatment of localized and metastatic renal cell carcinoma. Nephron-sparing surgery, laparoscopic nephrectomy, and energy-ablative techniques are now in the armamentarium of the urologist. The role of adrenalectomy and lymphadenectomy are better understood today than in decades past, and recent advances in the understanding of immunotherapy, cytoreductive nephrectomy, and metastatic disease have also improved treatment for this disease. As is often the case as technology and knowledge evolve, controversies regarding the surgical treatment of renal cancer exist. This article outlines some of these controversies and reviews the evidence surrounding each.
Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim
Edited by Kerrin G. Robinson
Clin Oncol 2005 ; 23 : 8802 – 8811 . 13. Berchuck A Iversen ES Lancaster JM . Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays . Am J Obstet Gynecol 2004 ; 190
Robert J. Morgan Jr.
resulted in significant changes in recommendations. For example, data suggesting a correlation between patient survival and extent of initial surgical debulking resulted in strengthening recommendations. “Optimal” cytoreduction is defined as less than 1
Ashraf Z. Badros
at least a VGPR, supporting the hypothesis that post-transplantation thalidomide provides additional cytoreduction rather than eradication or suppression of minimal residual disease. Currently, however, initial response to therapy should not be used
Christopher M. McPherson and Raymond Sawaya
Surgery is an essential part of the oncologic treatment of patients with brain tumors. Surgery is necessary for histologic diagnosis, and the cytoreduction of tumor mass has been shown to improve patient survival time and quality of life. Ultimately, the goal of any oncologic neurosurgery is to achieve maximal safe resection. Over the years, many technologic adjuncts have been developed to assist the surgeon in achieving this goal. In this article, we review the technologic advances of modern neurosurgery that are helping to reach this goal.